
Shares of drug developer Acadia Pharmaceuticals ACAD.O rise 34.2% to over 1-year high of $23.61
U.S. District Court for the District of Delaware has ruled that India's Aurobindo Pharma infringes on two of Acadia Pharmaceuticals' patent claims
The court has rejected Aurobindo's arguments that they are invalid
The companies will meet to discuss next steps and submit a joint letter to the court within 21 days
Acadia will provide an update on its revised stipulation regarding the patent claims within 7 days
Companies must work together to redact sensitive information from the court's opinion and submit a proposed redacted version within 30 days
Including session's move, stock up 28.3% YTD